CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The BARDiag project aims to develop non-invasive blood tests for early detection of colorectal and lung cancers by targeting specific isoforms of the BARD1 gene. This approach seeks to improve diagnostic accuracy and patient outcomes.
Colorectal cancer and lung cancer cause millions of death each year.
Currently there is no suitable non-invasive method for the early detection of these types of cancer.
The tumour suppressor gene BARD1 (BRCA1-associated RING domain protein) is aberrantly expressed in several types of cancer and could be a diagnostic target for early cancer diagnosis in blood samples.
The overall objective of the project is to develop blood tests for the early detection of colorectal and lung cancer based on can…
BARD1AG SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Estonia, Tartu
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Germany, Leipzig
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Switzerland, Geneve
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Leipzig
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
